Migenix closes plan of arrangement

Migenix (TSX:MGI) has closed its plan of arrangement, receiving $4 million from Madison Pacific Properties and transferring substantially all of its operations to subsidiary BioWest Therapeutics. BioWest is expected to begin trading on Wednesday under the symbol BWE, when shares of Migenix will be delisted.  The plan was approved by shareholders and the British Columbia [...]

In conversation with Paul Brennan

On Oct. 22, long-time biotech executive Paul Brennan took over the reins of Migenix (TSX:MGI), clearly with his work cut out for him.  In April, United Therapeutics walked away from an option agreement to develop Migenix’s Celgosivir anti-viral treatment for Hepatitis C.  Then in May, Cadence Pharmaceuticals walked away from a deal to develop Migenix’s [...]